Celgene Corp (USD)
CELG
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
IndustryDrug Manufacturers - Major
Day Range102.40 | 103.50
52-Wk Range58.59 | 103.08
Last Close102.95
Mkt Cap (m)72,964.91
Dividend yield-
ISINUS1510201049
Volume2,205,141
Exchange VenueNAS

Company Profile

Celgene Corp is a biotech company that discovers, develops, and commercializes therapies designed to treat cancer and immune-inflammatory related diseases. Its registered brands are Abraxane, Istodax, Otezla, Pomalyst, Revlimid, Thalomid, Vidaza.

Key Information
Price/Earning14.10
Price/Book7.26
Price/Sales4.53
P/CF9.38
Rev Growth (3 year avg)18.19
EPS Growth (3 year avg)0.42
Operating Margin % 34.70
Net Margin %26.48
Return on Equity61.86
Debt/Equity3.29

Legal Documents

Prospectus
en 12/02/2018
Annual Report
en 31/12/2018

Financials

Income Statement
USD201320142015201620172018
Revenue (m)6,4947,6709,25611,22913,00315,281
Operating Income (m)1,9802,5682,5543,2043,3575,303
Net Income (m)1,4502,0001,6021,9992,9404,046
Basic EPS1.752.492.022.573.775.65
Avg. Diluted Shares Outstanding (m)861836825803809734
Balance Sheet
USD201320142015201620172018
Current Assets (m)7,5519,7139,40110,86814,8929,067
Non Current Assets (m)5,8287,62817,65317,21815,24926,413
Total Assets (m)13,37817,34027,05328,08630,14135,480
Current Liabilities (m)1,9462,1121,9692,9592,9874,057
Total Liabilities (m)------
Total Equity (m)5,5906,5255,9196,5996,9216,161
Cash Flows
USD201320142015201620172018
Operating Cash Flows (m)2,2262,8062,4843,9765,2465,171
Capital Expenditure (m)-139-175-286-236-279-330
Figures are quoted in USD unless stated otherwise
0.31 (0.30%)
$
103.26
Last Price